Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic drug bill

Executive Summary

Legislation to increase FDA enforcement authority is expected to be introduced on May 15 by Rep. Dingell (D-Mich.), whose House Oversight Subcommittee has investigated the generic drug scandal for nearly two years. The measure will be referred to the Health Subcommittee, chaired by Rep. Waxman (D-Calif.), who will not be a cosponsor. Waxman reportedly is concerned that the bill's sanctions solely target the generic and not the brandname industry and that the HHS Inspector General's enforcement authority might supersede FDA's regarding FD&C Act felony violations.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel